Skye Bioscience, Company Insiders
SKYE Stock | USD 2.86 0.15 4.98% |
Skye Bioscience,'s insiders are aggressively selling. The analysis of the overall insider sentiment regarding Skye Bioscience, Common suggests that all insiders are panicking. Skye Bioscience, employs about 11 people. The company is managed by 6 executives with a total tenure of roughly 26 years, averaging almost 4.0 years of service per executive, having 1.83 employees per reported executive.
Skye Bioscience,'s Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-11-18 | Tuan Tu Diep | Disposed 19489 @ 4.99 | View | ||
2024-11-15 | Tuan Tu Diep | Disposed 85 @ 5.55 | View | ||
2024-09-13 | Andrew J Schwab | Disposed 13837 @ 6.06 | View | ||
2024-09-11 | Andrew J Schwab | Disposed 252500 @ 6.6 | View |
Monitoring Skye Bioscience,'s insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Skye |
Skye Bioscience,'s Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Skye Bioscience,'s future performance. Based on our forecasts, it is anticipated that Skye will maintain a workforce of about 11 employees by January 2025.Skye Bioscience, Management Team Effectiveness
The company has return on total asset (ROA) of (0.3039) % which means that it has lost $0.3039 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5482) %, meaning that it created substantial loss on money invested by shareholders. Skye Bioscience,'s management efficiency ratios could be used to measure how well Skye Bioscience, manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 18.54, whereas Return On Tangible Assets are forecasted to decline to (3.31). At present, Skye Bioscience,'s Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 12.2 M, whereas Total Assets are forecasted to decline to about 6 M.As of December 20, 2024, Common Stock Shares Outstanding is expected to decline to about 6.7 M. In addition to that, Net Loss is expected to decline to about (8.1 M)
Skye Bioscience, Workforce Comparison
Skye Bioscience, Common is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 1,865. Skye Bioscience, maintains roughly 11.0 in number of employees contributing less than 1% to equities under Health Care industry.
Skye Bioscience, Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Skye Bioscience, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Skye Bioscience,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Skye Bioscience, insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-12-01 | 1.0 | 8 | 8 | 1,250,000 | 232,431 |
2024-09-01 | 0.25 | 3 | 12 | 280,727 | 532,674 |
2023-03-01 | 2.0 | 8 | 4 | 59,520,650 | 16,641,486 |
2021-12-01 | 6.0 | 6 | 1 | 9,710,000 | 400,000 |
2020-09-01 | 3.5 | 7 | 2 | 16,750,000 | 5,566,666 |
2019-12-01 | 0.5 | 1 | 2 | 40,800,000 | 44,880,000 |
2018-12-01 | 6.0 | 6 | 1 | 3,937,667 | 0.00 |
2018-03-01 | 0.8889 | 8 | 9 | 72,016,250 | 54,519,484 |
2015-09-01 | 1.0 | 2 | 2 | 343,750 | 110,000 |
2015-06-01 | 0.4286 | 3 | 7 | 52,000 | 541,880 |
2014-12-01 | 1.1429 | 8 | 7 | 1,730,000 | 8,151,460 |
Skye Bioscience, Notable Stakeholders
A Skye Bioscience, stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Skye Bioscience, often face trade-offs trying to please all of them. Skye Bioscience,'s stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Skye Bioscience,'s stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Punit BA | President Chairman | Profile | |
BA BA | President, Chairman | Profile | |
Kaitlyn CPA | Chief Officer | Profile | |
FACE MD | Chief Officer | Profile | |
Tu MSc | Chief Officer | Profile | |
Christopher Twitty | Chief Officer | Profile |
About Skye Bioscience, Management Performance
The success or failure of an entity such as Skye Bioscience, Common often depends on how effective the management is. Skye Bioscience, management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Skye management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Skye management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (3.15) | (3.31) | |
Return On Capital Employed | 6.97 | 3.58 | |
Return On Assets | (3.15) | (3.31) | |
Return On Equity | 17.66 | 18.54 |
Please note, the presentation of Skye Bioscience,'s financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Skye Bioscience,'s management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Skye Bioscience,'s management manipulating its earnings.
Skye Bioscience, Workforce Analysis
Traditionally, organizations such as Skye Bioscience, use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Skye Bioscience, within its industry.Skye Bioscience, Manpower Efficiency
Return on Skye Bioscience, Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 3.4M | |
Net Loss Per Executive | 6.3M |
Complementary Tools for Skye Stock analysis
When running Skye Bioscience,'s price analysis, check to measure Skye Bioscience,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Skye Bioscience, is operating at the current time. Most of Skye Bioscience,'s value examination focuses on studying past and present price action to predict the probability of Skye Bioscience,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Skye Bioscience,'s price. Additionally, you may evaluate how the addition of Skye Bioscience, to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Transaction History View history of all your transactions and understand their impact on performance | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |